Brands
Crompton fans greener future with ambitious 2035 goals
MUMBAI: Crompton is turning up the heat on sustainability. India’s leading consumer electricals brand, Crompton Greaves Consumer Electricals Ltd, has unveiled its ambitious 2035 sustainability roadmap, pledging to halve Scope 1 and 2 greenhouse gas emissions and cut ceiling fan emission intensity by 60 per cent against 2022 levels.
The company has completed detailed carbon assessments across seven major product categories, including fans, pumps, lighting and appliances, and is embedding Design for Sustainability (DfS) principles to ensure future products are environmentally responsible without compromising on performance. Crompton’s Highspeed 48 ceiling fan has already earned the CII Greenpro Certification, and the company aims to replicate ecolabel certifications across all key categories by 2030.
Solar power forms a central part of the strategy. Crompton is expanding its solar portfolio through rooftop installations, solar lighting solutions, and active participation in solar pump tenders. Manufacturing facilities, starting with those having the highest emissions, will increasingly run on renewable energy, contributing to a low-carbon value chain.
To track progress, a centralised ESG dashboard has been deployed across major locations, enabling real-time monitoring of emissions, water and waste. This data-driven approach has allowed Crompton to complete a fully verified ESG audit for FY25. In parallel, a Sustainable supply chain code of conduct will engage key vendors in structured emissions tracking and reduction, extending the climate action beyond internal operations.
MD & CEO Promeet Ghosh said, “Our products impact the environment and are impacted by it. Climate change is shaping consumer behaviour, and we are mindful of our products’ environmental footprint. Sustainability is not just a responsibility but a driver of smarter innovation, product differentiation and consumer affinity. Our mission is clear: to build a resilient, low-carbon business offering sustainable products at affordable prices.”
Crompton’s commitment has already earned global recognition, ranking 4th worldwide in the household durables sector in the S&P Global Corporate Sustainability Assessment 2024 and inclusion in the S&P Global Sustainability Yearbook 2025. Domestically, Crompton has won multiple National Energy Consumer Awards and has been lauded as one of India’s Best Managed Companies 2022.
With 85 years of legacy and a track record of innovation in fans, pumps, lighting, and other home appliances, Crompton is setting a new benchmark for consumer durables in India, proving that performance, innovation and environmental responsibility can move forward hand in hand.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
